Effects of Antidepressant Treatment on Neurotrophic Factors (BDNF and IGF-1) in Patients with Major Depressive Disorder (MDD)
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) remains the subject of ongoing research as a multifactorial disease and a serious public health problem. There is a growing body of literature focusing on the role of neurotrophic factors in pathophysiology of MDD. A neurotrophic hypothesis of depression proposes that abnormalities of neurotrophins serum levels lead to neuronal atrophy and decreased neurogenesis, resulting in mood disorders. Consequently, in accordance with recent findings, antidepressant treatment modifies the serum levels of neurotrophins and thus leads to a clinical improvement of MDD. The purpose of this review is to summarize the available data on the effects of various antidepressants on serum levels of neurotrophins such as brain-derived neurotrophic factor (BDNF) and insulin-like growth factor (IGF-1). In addition, the authors discuss their role as prognostic factors for treatment response in MDD. A literature search was performed using the PubMed database. Following the inclusion and exclusion criteria, nine original articles and three meta-analyses were selected. The vast majority of studies have confirmed the effect of antidepressants on BDNF levels. Research on IGF-1 is limited and insufficient to describe the correlation between different antidepressant drugs and factor serum levels; however, four studies indicated a decrease in IGF-1 after treatment. Preliminary data suggest BDNF as a promising predictor of treatment response in MDD patients. The role of IGF-1 needs further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conventional antidepressants, including selective serotonin reuptake inhibitors (SSRIs), have been shown to gradually increase BDNF levels with chronic treatment, which correlates with their delayed therapeutic onset [2,7].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“traditional antidepressants, which have been shown to increase BDNF levels both peripherally and in targeted brain regions.”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“The aim of the study was to assess how antidepressants affect the level of neurotrophic markers and whether they could be a predictor of response to antidepressants [49,50].”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“Early studies conducted on rats assessing antidepressant responses showed that conventional antidepressant drugs, as well as electroconvulsive therapy (ECT), enhanced expression of BDNF and TrkB mRNA in the hippocampus and cortical regions in a timeframe similar to the onset of the antidepressant-like response [52,53].”
Background(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.7.979 · Cited by 1,485 · cited 1×
“Depression is the most commonly diagnosed mental disorder [1].”
BackgroundCytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Decreased serum brain-derived neurotrophic factor levels in major depressed patients
Karege, F., Perret, G., Bondolfi, G., Schwald, M., Bertschy, G., & Aubry, J.-M. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00005-7 · Cited by 1,232
Nibuya, M., Nestler, E., & Duman, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-07-02365.1996 · Cited by 1,206
Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication
Chen, B., Dowlatshahi, D., MacQueen, G. M., Wang, J.-F., & Young, L. T. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01083-6 · Cited by 1,164
Brunoni, A. R., Lopes, M., & Fregni, F. (2008) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009309 · Cited by 972
BDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“According to the neurotrophic hypothesis of depression, the deficiency of BDNF and other growth factors may contribute to the atrophy of certain limbic structures, including the hippocampus and prefrontal cortex, observed in patients with depression, and antidepressant drugs act by increasing the levels of BDNF [16,18…”
BackgroundMolendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 1×
“included patients with moderate depressive episode severity (defined as a Hamilton Depression Rating Score, 17 items (HDRS) ≥ 17) [20].”
BackgroundMaes, M., Leonard, B. E., Myint, A. M., Kubera, M., & Verkerk, R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.017 · Cited by 700
Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects
Mahar, I., Bambico, F. R., Mechawar, N., & Nobrega, J. N. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.009 · Cited by 694
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617
Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.014 · Cited by 544
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538 · cited 1×
“Signaling via BDNF and its receptor, tropomycin receptor kinase B (TrkB), plays a key role in the pathophysiology of depression and in the therapeutic mechanisms of antidepressants [24].”
BackgroundPolyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., & Schroeter, M. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.11.044 · Cited by 488 · cited 2×
“meta-analyzed 21 (n = 735) studies concerning pre- and post-treatment serum and plasma BDNF levels according to treatment response in MDD patients [36].”
ResultDyer, A. H., Vahdatpour, C., Sanfeliu, A., & Tropea, D. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.03.056 · Cited by 377
Effect of treatment on serum brain–derived neurotrophic factor levels in depressed patients
Gonul, A. S., Akdeniz, F., Taneli, F., Donat, O., Eker, Ç., & Vahip, S. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0578-6 · Cited by 375 · cited 1×
“For SNRI, three drugs (vortioxetine, venlafaxine and duloxetine) were used, six reported increase of BDNF [41,42,54,59,63,65], one was ambiguous [64] and two did not report an increase (both of them used venlafaxine) [39,55].”
MethodSharma, T., Guski, L. S., Freund, N., & Gøtzsche, P. C. (2016) · BMJ · doi:10.1136/bmj.i65 · Cited by 319
Cytokines and depression: The need for a new paradigm
Capuron, L., & Dantzer, R. (2003) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00078-8 · Cited by 280
Phillips, M. L., Chase, H. W., Sheline, Y. I., Etkin, A., Almeida, J. R. C., Deckersbach, T., & Trivedi, M. H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14010076 · Cited by 267
Neurotrophin signalling: novel insights into mechanisms and pathophysiology
Mitre, M., Mariga, A., & Chao, M. V. (2017) · Clinical Science · doi:10.1042/cs20160044 · Cited by 263
Matrisciano, F., Bonaccorso, S., Ricciardi, A., Scaccianoce, S., Panaccione, I., Wang, L., Ruberto, A., Tatarelli, R., Nicoletti, F., Girardi, P., et al. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.03.014 · Cited by 253
The responsiveness of the Hamilton Depression Rating Scale
Faries, D., Herrera, J., Rayamajhi, J., DeBrota, D., Demitrack, M., & Potter, W. Z. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00037-0 · Cited by 232
BDNF: a neuromodulator in nociceptive pathways?
Pezet, S., Malcangio, M., & McMahon, S. B. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00206-0 · Cited by 218
Inflammatory mechanisms in major depressive disorder
Raedler, T. J. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834b9db6 · Cited by 213
Brain-derived neurotrophic factor (BDNF) changes in the serum of depressed women
Aydemir, C., Yalcin, E. S., Aksaray, S., Kisa, C., Yildirim, S. G., Uzbay, T., & Goka, E. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.025 · Cited by 211
Behr, G. A., Moreira, J. C. F., & Frey, B. N. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/609421 · Cited by 205
Inflammatory theory of depression
Gałecki, P., & Talarowska, M. (2018) · Psychiatria Polska · doi:10.12740/pp/76863 · Cited by 192
Zhou, C., Zhong, J., Zou, B., Fang, L., Chen, J., Deng, X., Zhang, L., Zhao, X., Qu, Z., Lei, Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172270 · Cited by 187 · cited 2×
“examined 20 studies to assess the effect of antidepressant drugs on the BDNF levels before and after treatment [37].”
BackgroundThe anti-inflammatory mechanism of antidepressants – SSRIs, SNRIs
Gałecki, P., Mossakowska-Wójcik, J., & Talarowska, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.016 · Cited by 180
Yoshimura, R., Mitoma, M., Sugita, A., Hori, H., Okamoto, T., Umene, W., Ueda, N., & Nakamura, J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.001 · Cited by 178
Toward a comprehensive neurobiology of IGF‐I
Torres‐Aleman, I. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20778 · Cited by 177
Serum BDNF levels before treatment predict SSRI response in depression
Wolkowitz, O. M., Wolf, J., Shelly, W., Rosser, R., Burke, H. M., Lerner, G. K., Reus, V. I., Nelson, J. C., Epel, E. S., & Mellon, S. H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.06.013 · Cited by 174
Sharma, A. N., da Costa e Silva, B. F. B., Soares, J. C., Carvalho, A. F., & Quevedo, J. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.067 · Cited by 142 · cited 1×
“The mechanisms underlying the effectiveness of antidepressants may include an increase in BDNF, which is responsible for neuroplasticity in the nervous system [25,26].”
BackgroundMondal, A. C., & Fatima, M. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1527328 · Cited by 141
How to write an evidence-based clinical review article.
Siwek, J., Gourlay, M. L., Slawson, D. C., & Shaughnessy, A. F. (2002) · PubMed · Cited by 136
Hellweg, R., Ziegenhorn, A., Heuser, I., & Deuschle, M. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-1004594 · Cited by 127
Lee, H.-Y., & Kim, Y.-K. (2008) · Neuropsychobiology · doi:10.1159/000149817 · Cited by 123
Başterzi, A. D., Yazıcı, K. U., Aslan, E., Delıalıoğlu, N., Taşdelen, B., Acar, Ş. T., & Yazıcı, A. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.016 · Cited by 96
McCusker, R. H., McCrea, K., Zunich, S. M., Dantzer, R., Broussard, S. R., Johnson, R. W., & Kelley, K. W. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.06.014 · Cited by 92
Rauti, R., Cellot, G., D’Andrea, P., Colliva, A., Scaini, D., Tongiorgi, E., & Ballerini, L. (2020) · Molecular Brain · doi:10.1186/s13041-020-00582-9 · Cited by 78 · cited 1×
“It affects neuronal maturation, formation of synapses and synaptic plasticity [68] BDNF is also associated with the development of psychiatric disorders.”
BackgroundMikoteit, T., Beck, J., Eckert, A., Hemmeter, U., Brand, S., Bischof, R., Holsboer‐Trachsler, E., & Delini‐Stula, A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3475-8 · Cited by 72
Possible contribution of IGF-1 to depressive disorder
Szczęsny, E., Ślusarczyk, J., Głombik, K., Budziszewska, B., Kubera, M., Lasoń, W., & Basta-Kaim, A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71523-8 · Cited by 68 · cited 2×
“It has been proven to act on the function of synapses, the metabolism of brain cells and to have neuroprotective properties [29,30].”
BackgroundIGF-I in major depression and antidepressant treatment response
Kopczak, A., Stalla, G. K., Uhr, M., Lucae, S., Hennings, J., Ising, M., Holsboer, F., & Kloiber, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.013 · Cited by 63
Gupta, R., Gupta, K., Tripathi, A. K., Bhatia, M. S., & Gupta, L. K. (2016) · Pharmacology · doi:10.1159/000444220 · Cited by 61 · cited 3×
“[40] 2017 B Clinical Trial n = 60 (agomelatine = 30 fluoxetine = 30) 12 serum BDNF Fluoxetine, Agomelatine YES Agomelatine responders—serum BDNF level significantly increased at 12 weeks after treatment.”
BackgroundMethodBrunoni, A. R., Machado-Vieira, R., Zarate, C. A., Vieira, E. L. M., Vanderhasselt, M.-A., Nitsche, M. A., Valiengo, L., Benseñor, I. M., Lotufo, P. A., Gattaz, W. F., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.006 · Cited by 60 · cited 6×
“According to the neurotrophic hypothesis of depression, the deficiency of BDNF and other growth factors may contribute to the atrophy of certain limbic structures, including the hippocampus and prefrontal cortex, observed in patients with depression, and antidepressant drugs act by increasing the levels of BDNF [16,18…”
BackgroundMethodInfluentialDeuschle, M., Gilles, M., Scharnholz, B., Lederbogen, F., Lang, U., & Hellweg, R. (2012) · Pharmacopsychiatry · doi:10.1055/s-0032-1321908 · Cited by 60
Fornaro, M., Rocchi, G., Escelsior, A., Contini, P., & Martino, M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.08.007 · Cited by 59 · cited 1×
“[66] 12 n = 30 ↑ early non-responders, ↔ early responders”
Bot, M., Milaneschi, Y., Penninx, B. W. J. H., & Drent, M. L. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.028 · Cited by 50
Umene-Nakano, W., Yoshimura, R., Ueda, N., Suzuki, A., Ikenouchi-Sugita, A., Hori, H., Otani, K., & Nakamura, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106899 · Cited by 46
Šagud, M., Perković, M. N., Vuksan‐Ćusa, B., Maravić, A., Štrac, D. Š., Peleš, A. M., Živković, M., Kušević, Z., & Pivac, N. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4364-0 · Cited by 46
Katsuki, A., Yoshimura, R., Kishi, T., Hori, H., Umene-Nakano, W., Ikenouchi-Sugita, A., Hayashi, K., Atake, K., Iwata, N., & Nakamura, J. (2012) · CNS Spectrums · doi:10.1017/s109285291200051x · Cited by 42
Chiou, Y.-J., & Huang, T.-L. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw096 · Cited by 38
An overview of SSRI and SNRI therapies for depression.
Weilburg, J. B. (2004) · PubMed · Cited by 37
Ghosh, R., Gupta, R., Bhatia, M. S., Tripathi, A. K., & Gupta, L. K. (2015) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2015.10.006 · Cited by 37
Belzeaux-R, R., Lin, C., Ding, Y., Bergon, A., Ibrahim, E. C., Turecki, G., Tseng, G. C., & Sibille, E. L. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.009 · Cited by 32
Chen, M., Zhang, L., & Jiang, Q. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1967 · Cited by 28
Arumugam, V., John, V., Augustine, N., Jacob, T., Joy, S., Sen, S., & Sen, T. (2017) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_700_16 · Cited by 27
Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders
Baldwin, D. S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600637056 · Cited by 26
Troyan, A. S., & Levada, O. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00800 · Cited by 26
Levada, O. A., Troyan, A. S., & Пінчук, І. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02636-7 · Cited by 24
Neuroinflammation and Immunity: A New Pharmacological Target in Depression
Crupi, R., & Cuzzocrea, S. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160321105339 · Cited by 20
Zheng, W., Zhou, Y., Wang, C., Lan, X., Zhang, B., Zhou, S., Yan, S., & Ning, Y. (2021) · PeerJ · doi:10.7717/peerj.10989 · Cited by 18
[Major depressive disorders and BDNF (brain-derived neurotrophic factor)].
Shimizu, E., Hashimoto, K., & Iyo, M. (2004) · PubMed · Cited by 12
Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective
Levada, O. A., & Troyan, A. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109610 · Cited by 12
Research works printed but not linked: 1
- Jacobs, 1999, Chronic fluoxetine treatment increases hippocampal neurogenesis in rats: A novel theory of depression, Soc. Neurosci. Abstr., 25, 714
Cited by
Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis
Wu, A., & Zhang, J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02964-x · Cited by 306
Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders
Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., Xu, S., Wang, F., & Huang, J. H. (2022) · Pharmaceuticals · doi:10.3390/ph15101203 · Cited by 253
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
Liu, X., Li, P., Ma, X., Zhang, J., Sun, X., Luo, X., & Zhang, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.041 · Cited by 34
Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
Metadata
- Authors
- Mosiołek, A., Mosiołek, J., Jakima, S., Pięta, A., & Szulc, A.
- Affiliations
- Medical University of Warsaw (PL)
- Wroclaw Medical University (PL)
- Mazovia Specialist Health Center in Pruszków, Partyzantów 2/4 Street, 05-802 Pruszków, Poland
- Corresponding author
- Mosiołek, Anna
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-07-30
- Volume
- 10
- Issue
- 15
- Pages
- 3377
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC8346988
- OpenAlex
- W3189411429
- Cited by
- 87
- References
- 71
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 24 · 2023: 16 · 2022: 13
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- major depressive disorder, antidepressants, brain-derived neurotrophic factor, insulin-like growth factor I, neurotrophic factors, serum biomarkers, treatment response prediction, neurogenesis, neuronal atrophy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
